RENOVACOR INC (RCOR) Stock Price, Quote, News and Overview
NYSEARCA:RCOR - NYSE Arca - US75989E1064 - Common Stock - Currency: USD
RCOR Quote, Performance and Key Statistics
3.2
+0.15 (+4.92%)
The current stock price of RCOR is 3.2 USD. In the past month the price increased by 4.92%. In the past year, price decreased by -61.86%.
RCOR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About RCOR
Company Profile
Renovacor, Inc. operates as a clinical stage gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 19 full-time employees. The company went IPO on 2020-04-24. The firm is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. The firm's therapeutic focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM). The firm is also conducting preclinical studies exploring the ability of a BAG3 gene therapy to treat patients suffering from DCM caused by BAG3 haploinsufficiency. The Company’s preclinical strategy is to advance earlier stage research programs of its BAG3 gene therapy. Its research and discovery programs include BAG3- mediated diseases associated with the cardiovascular system and the central nervous system.
Company Info
RENOVACOR INC
201 Broadway, Suite 310
Cambridge MASSACHUSETTS US
CEO: Jonas Grossman
Employees: 19
Company Website: https://renovacor.com
Phone: 16104242650.0
RENOVACOR INC / RCOR FAQ
What is the stock price of RENOVACOR INC today?
The current stock price of RCOR is 3.2 USD. The price increased by 4.92% in the last trading session.
What is the ticker symbol for RENOVACOR INC stock?
The exchange symbol of RENOVACOR INC is RCOR and it is listed on the NYSE Arca exchange.
On which exchange is RCOR stock listed?
RCOR stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for RENOVACOR INC stock?
11 analysts have analysed RCOR and the average price target is 7.13 USD. This implies a price increase of 122.73% is expected in the next year compared to the current price of 3.2. Check the RENOVACOR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RENOVACOR INC worth?
RENOVACOR INC (RCOR) has a market capitalization of 55.26M USD. This makes RCOR a Micro Cap stock.
How many employees does RENOVACOR INC have?
RENOVACOR INC (RCOR) currently has 19 employees.
What are the support and resistance levels for RENOVACOR INC (RCOR) stock?
RENOVACOR INC (RCOR) has a support level at 2.91 and a resistance level at 3.21. Check the full technical report for a detailed analysis of RCOR support and resistance levels.
Should I buy RENOVACOR INC (RCOR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RCOR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RCOR, evaluating the profitability, health, valuation and growth aspects
- RENOVACOR INC (RCOR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RENOVACOR INC (RCOR) Sales and EPS estimates to see what analysts future expectations are.
- RENOVACOR INC (RCOR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RENOVACOR INC (RCOR) Insider and Institutional Ownership to learn about the owners and their transactions.
- RENOVACOR INC (RCOR) Stock Chart to make your own analysis
- RENOVACOR INC (RCOR) Latest news and press-releases to stay up to date.
Does RENOVACOR INC (RCOR) stock pay dividends?
RCOR does not pay a dividend.
When does RENOVACOR INC (RCOR) report earnings?
RENOVACOR INC (RCOR) will report earnings on 2023-03-22.
What is the Price/Earnings (PE) ratio of RENOVACOR INC (RCOR)?
RENOVACOR INC (RCOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.2).
RCOR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RCOR. When comparing the yearly performance of all stocks, RCOR is one of the better performing stocks in the market, outperforming 90.69% of all stocks.
RCOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RCOR. While RCOR seems to be doing ok healthwise, there are quite some concerns on its profitability.
RCOR Financial Highlights
Over the last trailing twelve months RCOR reported a non-GAAP Earnings per Share(EPS) of -1.2. The EPS increased by 48.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.84% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
RCOR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to RCOR. The Buy consensus is the average rating of analysts ratings from 11 analysts.